摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Benzyl-(2R) 2-benzyl-3-morpholinocarbonylpropionate | 116129-89-6

中文名称
——
中文别名
——
英文名称
Benzyl-(2R) 2-benzyl-3-morpholinocarbonylpropionate
英文别名
benzyl (2R)-2-Benzyl-3-morpholinocarbonylpropionate;benzyl (2R)-2-benzyl-4-morpholin-4-yl-4-oxobutanoate
Benzyl-(2R) 2-benzyl-3-morpholinocarbonylpropionate化学式
CAS
116129-89-6
化学式
C22H25NO4
mdl
——
分子量
367.445
InChiKey
LIOBQBJHDBLVOX-HXUWFJFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Benzyl-(2R) 2-benzyl-3-morpholinocarbonylpropionate 在 palladium on activated charcoal 氢气 作用下, 以 甲醇 为溶剂, 反应 1.5h, 生成 (2R)-2-benzyl-3-(morpholinocarbonyl)propionic acid
    参考文献:
    名称:
    1,2,3-三取代环丙烷作为构象受限的肽等排物:在新型肾素抑制剂的设计和合成中的应用。
    摘要:
    1,2,3-三取代的环丙烷6和7是肽连接的新型等位取代的第一类成员,肽连接通常由二肽模拟物2和3代表。这些独特的肽替代物专门设计用于锁定一个区域以扩展的β-链构象(phi-角度限制)形成肽主链,同时对氨基酸侧链实施两个明确定义的取向之一(x 1角度限制)。首先开发了一种以Rh2(S-MEPY)4为特征的有效方法,用于立体选择性,不对称合成三取代环丙烷15a-d,18a-d,22a-d和23a-d(方案II)的方法(11 )和Rh2(R-MEPY)4(20)催化烯丙基重氮乙酸酯10a-d的环化反应,分别得到旋光内酯12a-d和21a-d,对映体过量大于或等于94%。12a-d的内酯环的亲核开环得到相应的吗啉酰胺14a-d。通过利用允许在环丙烷核上的两个官能化侧链之一进行选择性差向异构化的策略,将14a-d转变为两个系列的非对映异构吗啉酰胺羧酸15a-d和18a-d。14a-d发生吗啉酰胺基的
    DOI:
    10.1021/jm00088a005
  • 作为产物:
    参考文献:
    名称:
    Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability
    摘要:
    A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.
    DOI:
    10.1021/jm00120a006
点击查看最新优质反应信息

文献信息

  • Renin-inhibiting functionalized peptidyl aminodiols and - triols
    申请人:ABBOTT LABORATORIES
    公开号:EP0341602A2
    公开(公告)日:1989-11-15
    A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.
    一个公式为的抑制肾素的化合物: 或其药用可接受的盐、酯或前药。
  • Peptidyl difluorodiol renin inhibitors
    申请人:ABBOTT LABORATORIES
    公开号:EP0416393A1
    公开(公告)日:1991-03-13
    A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH₂- or (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-; Q is -CH(R₁)- or -C(=CHR1a)- wherein R₁ is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R₃ is a functional group; R₄ is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R₅ is -CH(OH)- or -C(O)-; R₆ is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
    一种肾素抑制化合物的化学式:其中A是一个功能基团;W是(1) -C(O)-,(2) -CH(OH)-或(3) -N(R₂)-,其中R₂是氢或较低烷基;U是(1) -C(O)-,(2) -CH₂-或(3) -N(R₂)-,其中R₂是氢或较低烷基,但当W为-CH(OH)-时,则U为-CH₂-,并且当U为-N(R₂)-时,U为-C(O)-或-CH₂-;V是(1) -CH-,(2) -C(OH)-或(3) -C(卤素)-,但当U为-N(R₂)-时,V为-CH-;Q是-CH(R₁)-或-C(=CHR1a)-,其中R₁是(1) 较低烷基,(2) 环烷基烷基,(3) 芳基烷基,(4) (杂环)烷基,(5) 1-苄氧乙基,(6) 苯氧基,(7) 噻吩氧基或(8) 氨基苯基,前提是当R₁是苯氧基、噻吩氧基或氨基苯基时,B是-CH₂-或-CH(OH)-,或A是氢,而R1a是芳基或杂环;R₃是一个功能基团;R₄是(1) 较低烷基,(2) 环烷基甲基或(3) 苄基;R₅是-CH(OH)-或-C(O)-;R₆是-CH(OH)-或-C(O)-;Z是(1) 较低烷基,(2) 芳基,(3) 芳基烷基,(4) 环烷基,(5) 环烷基烷基,(6) 杂环或(7) (杂环)烷基;或其药学上可接受的盐、酯或前药。
  • Renin-inhibiting peptidyl heterocycles
    申请人:ABBOTT LABORATORIES
    公开号:EP0307837A3
    公开(公告)日:1991-12-11
    A renin inhibiting compound of the formula: wherein A is a substituent; W is C=O, CHOH or NR₂ wherein R₂ is hydrogen or loweralkyl; U is C=O, CH₂ or NR₂ wherein R₂ is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH₂ and with the proviso that U is C=O or CH₂ when W is NR₂; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR₂; R₁ is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH₂ or CHOH or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino; R₃ is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl, (alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R₄ is loweralkyl, cycloalkylmethyl or benzyl; R₅ is OH or NH₂; and Z is a substituent.Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.
    一种抑制肾素的化合物,其结构式为:其中A是取代基;W为C=O、CHOH或NR₂,其中R₂为氢或较低的烷基;U为C=O、CH₂或NR₂,其中R₂为氢或较低的烷基,但当W为CHOH时,U为CH₂,且当U为C=O或CH₂时,W为NR₂;V为CH、C(OH)或C(卤素),但当U为NR₂时,V为CH;R₁为较低的烷基、环烷基烷基、苄基、(α,α)-二甲基苄基、4-甲氧基苄基、卤代苄基、4-羟基苄基、(1-萘基)甲基、(2-萘基)甲基、(未取代的杂环)甲基、(取代的杂环)甲基、苯乙基、1-苄氧基乙基、苯氧基、硫代苯氧基或苯胺基,但当R₁为苯氧基、硫代苯氧基或苯胺基时,B为CH₂或CHOH或A为氢;R₃为较低的烷基、较低的烯基、((烷氧基)烷氧基)烷基、羧基烷基、(硫代烷氧基)烷基、叠氮基烷基、氨基烷基、(烷基)氨基烷基、二烷基氨基烷基、(烷氧基)(烷基)氨基烷基、(烷氧基)氨基烷基、苄基或取代的杂环环取代的甲基;R₄为较低的烷基、环烷基甲基或苄基;R₅为OH或NH₂;Z为取代基。还披露了用于治疗高血压的组合物、制备抑制肾素化合物的方法以及制备抑制肾素化合物的中间体的方法。
  • Renin inhibiting compounds
    申请人:Abbott Laboratories
    公开号:US04826815A1
    公开(公告)日:1989-05-02
    The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; Or.sub.10 wherein R.sub.10 is hydrogen or loweralkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen and loweralkyl; or R.sub.13 --CO--B wherein B is NH, O, CH.sub.2, HNCH.sub.2 and R.sub.13 is loweralkyl, alkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, N-protected aminoalkyl, hydroxylated dialkylamino, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic, carboxyalkyl, or lower alkyl carboxyalkyl esters; W is N or CH: U,V may be the following combinations H,OH; OH,H; H,H; or when taken together as O represents a carbonyl with the provisos that if U,V.dbd.H,OH, then W=CH, and if U,V.dbd.O then W.dbd.N; R.sub.1 , R.sub.3 and R.sub.5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R.sub.2, R.sub.4, R.sub.7, R.sub.8 and R.sub.9 are hydrogen or loweralkyl and may be the same or different; X is NH, O, S, SO, SO.sub.2, or CH.sub.2 ; and R.sub.6 is loweralkyl cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protecting group, with the proviso that R.sub.6 may be an N-protecting group when X is NH.
    该发明涉及以下结构的抑制肾素化合物 ##STR1## 其中A为氢;loweralkyl;arylalkyl;Or.sub.10,其中R.sub.10为氢或loweralkyl;NR.sub.11 R.sub.12,其中R.sub.11和R.sub.12分别独立选择自氢和loweralkyl;或R.sub.13 --CO--B,其中B为NH,O,CH.sub.2,HNCH.sub.2,R.sub.13为loweralkyl,alkoxy,arylalkoxy,arylalkoxyalkyl,氨基,烷基氨基,二烷基氨基,氨基烷基,N-保护氨基烷基,羟基化的二烷基氨基,(杂环)烷基或取代或未取代的杂环,羧基烷基或lower alkyl羧基酯;W为N或CH;U,V可以是以下组合H,OH;OH,H;H,H;或当作为O一起取时表示一个羰基,但有条件是如果U,V=dbd.H,OH,则W=CH,如果U,V=dbd.O,则W=dbd.N;R.sub.1,R.sub.3和R.sub.5为loweralkyl或亲水性,亲脂性或芳香族氨基酸侧链,可以相同也可以不同;R.sub.2,R.sub.4,R.sub.7,R.sub.8和R.sub.9为氢或loweralkyl,可以相同也可以不同;X为NH,O,S,SO,SO.sub.2,或CH.sub.2;R.sub.6为loweralkyl环烷基,环烷基烷基,芳香族,芳基烷基或N-保护基,但有条件是当X为NH时R.sub.6可以是N-保护基。
  • LULY, JAY R.;DELLARIA, JOSEPH;FUNG, ANTHONY K. L.;KEMPF, DALE J.;PLATTNER+
    作者:LULY, JAY R.、DELLARIA, JOSEPH、FUNG, ANTHONY K. L.、KEMPF, DALE J.、PLATTNER+
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐